

Neurotech

Neurotech's updated Mente Autism device receives approval from regulatory body, Italcert

Perth, Australia & Malta – 4 June 2018 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions improving the lives of children with autism, announces that Italcert, its independent regulator for CE compliance, has approved considerable improvements to the Mente Autism device.

Italcert's approval means Neurotech can move ahead with the production process of the next batch of Mente Autism, which is expected to occur this month, and release the product to market in Europe.

As noted in the March quarterly update, the design improvements to the next iteration of the Mente Autism device includes improvements to wi-fi connectivity, synchronisation and usability linked to the firmware and the Mente Autism application. The CE mark shows that the product complies with European health, safety and environmental protection legislation, and production of the next batch of the device is underway.

Wolfgang Storf, CEO of Neurotech International said: “This is another important milestone for the company. Over the past year, we have listened to feedback from our customers and distribution partners and many of the improvements we have introduced resulted from this feedback. Our distributors are looking forward to receiving the updated device, which is expected to be available in July.”

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder. Designed for home use, it helps relax the minds of children on the spectrum which in turn helps them to focus better and engage positively with their environment.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com